In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CEO Interview: Novartis' Dan Vasella

Executive Summary

Novartis has done better than most Pharmas over the past five years, though shareholders are still dissatisfied. But CEO Dan Vasella continues playing for the long-term -- pursuing R&D innovation and cost-effective dealmaking, all within a relatively conservative strategic framework.
Advertisement

Related Content

Novartis’ Exjade Label Expansion To Get Advisory Committee Review
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
Evolution in Strategies for Getting FDA Approvals
CEO Interview: AstraZeneca's David Brennan
Januvia: Defining Primary-Care Success and Risk
Novartis' M&A Machine
Novartis' M&A Machine
Novartis's Research Experiment
Novartis's Research Experiment

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel